IN2014DN10390A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10390A
IN2014DN10390A IN10390DEN2014A IN2014DN10390A IN 2014DN10390 A IN2014DN10390 A IN 2014DN10390A IN 10390DEN2014 A IN10390DEN2014 A IN 10390DEN2014A IN 2014DN10390 A IN2014DN10390 A IN 2014DN10390A
Authority
IN
India
Prior art keywords
human patient
nucleotides
treating
lung cancer
small cell
Prior art date
Application number
Other languages
English (en)
Inventor
Chen Duksin
Shoshi Tessler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2014DN10390A publication Critical patent/IN2014DN10390A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN10390DEN2014 2012-05-18 2013-05-17 IN2014DN10390A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
IN2014DN10390A true IN2014DN10390A (enExample) 2015-08-14

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10390DEN2014 IN2014DN10390A (enExample) 2012-05-18 2013-05-17

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP4122383B1 (en) 2010-05-08 2025-02-12 The Regents Of The University Of California Sem scanner sensing apparatus for early detection of ulcers
RU2013145869A (ru) 2011-03-15 2015-04-20 Дзе Юниверсити Оф Бритиш Коламбиа КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
US10182740B2 (en) 2015-04-24 2019-01-22 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
EP3454866A4 (en) * 2016-05-13 2020-01-08 Golden Biotechnology Corporation METHOD AND COMPOSITIONS FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER
CA3042103A1 (en) 2017-02-03 2018-08-09 Bruin Biometrics, Llc Measurement of susceptibility to diabetic foot ulcers
KR102492905B1 (ko) 2017-02-03 2023-01-31 브루인 바이오메트릭스, 엘엘씨 조직 생존률의 측정
GB2569922B (en) 2017-02-03 2022-02-02 Bruin Biometrics Llc Measurement of edema
GB2574945A (en) 2017-11-16 2019-12-25 Bruin Biometrics Llc Providing a continuity of care across multiple care settings
AU2018380431B2 (en) 2017-12-07 2024-10-24 Bruin Biometrics, Llc SEM trend analysis
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
PT3749181T (pt) 2018-02-09 2024-05-15 Bruin Biometrics Llc Deteção de lesões nos tecidos
AU2019359378B2 (en) 2018-10-11 2025-01-09 Bruin Biometrics, Llc Device with disposable element
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
CA2728449A1 (en) * 2008-06-18 2009-12-23 Abbott Laboratories P/gf-1 companion diagnostic methods and products
CA2836676A1 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
US20130310440A1 (en) 2013-11-21
WO2013173757A1 (en) 2013-11-21
UY34812A (es) 2013-12-31
AR091090A1 (es) 2014-12-30
BR112014028787A2 (pt) 2017-06-27
IL235459A0 (en) 2014-12-31
KR20150024843A (ko) 2015-03-09
CA2874092A1 (en) 2013-11-21
EA201492148A1 (ru) 2015-04-30
SG11201407649RA (en) 2014-12-30
EP2849761A1 (en) 2015-03-25
TW201402132A (zh) 2014-01-16
AU2013262589A1 (en) 2015-01-22
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21
WO2013173757A8 (en) 2015-04-30
CN104684564A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
PH12014502569A1 (en) Method for treating non-small cell lung cancer
PH12013502402A1 (en) Method for treating non-small cell lung cancer
NZ603901A (en) Vectors and sequences for the treatment of diseases
NZ715081A (en) Antisense oligomers and conjugates targeting pcsk9
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
MX359548B (es) Agentes de iarn modificados.
PH12015501953A1 (en) Substituted nucleotide analogs
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
BR112015009559A2 (pt) uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
WO2011005566A3 (en) Aptamer-targeted sirna to inhibit nonsense mediated decay
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
AU2009279857A8 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides
IN2014CN03921A (enExample)
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
WO2012145597A3 (en) Recombinant virus products and methods for inhibition of expression of myotilin
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer